Evaluation of LacTEST for the Diagnosis of Hypolactasia in Adults and Elderly Patients Presenting With Clinical Symptoms of Lactose Intolerance

NCT ID: NCT02636413

Last Updated: 2016-12-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

1 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-10-31

Study Completion Date

2016-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate both the impact of LacTEST on diagnostic thinking and on patient management, and its reproducibility (Test-Retest), for the diagnosis of hypolactasia in adults and elderly patients presenting with clinical symptoms of lactose intolerance.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lactose Intolerance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LacTEST

0,45 g of gaxilose po, once, per diagnostic test performed.

Group Type EXPERIMENTAL

gaxilose

Intervention Type DRUG

After gaxilose administration, urine collection, cuantification (firstly from 0 to 4 hours, and total urine from 0 to 5 hours), and xilose cuantification afterwards.

Hydrogen Breath Test

25 to 50 g of lactose po, once, per diagnostic test performed.

Group Type ACTIVE_COMPARATOR

lactose

Intervention Type DIETARY_SUPPLEMENT

After lactose administration, expired hydrogen measurement at pre-specified intervals.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

gaxilose

After gaxilose administration, urine collection, cuantification (firstly from 0 to 4 hours, and total urine from 0 to 5 hours), and xilose cuantification afterwards.

Intervention Type DRUG

lactose

After lactose administration, expired hydrogen measurement at pre-specified intervals.

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LacTEST Hydrogen Breath Test (HBT)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Adults of either sex, between 18 and 70 years old.
2. Capacity for understanding and giving the informed consent to participate in this study.
3. Patients with clinical suggestive of lactose intolerance, primary or secondary, who have not been diagnosed and that fulfil the requirements allowed by the gaxilose summary of product characteristics (SmPC).

Exclusion Criteria

1. Pregnant women or breast-feeding women.
2. Unable or reticent to give the informed consent or to comply with the study requirements.
3. Patients with glomerular filtration rate (GFR) less than 90 ml/min/1.73m2.
4. Portal hypertension: ascites, cirrhosis.
5. Medical records of total gastrectomy and/or vagotomy.
6. Patients diagnosed with myxedema.
7. Patients with Diabetes Mellitus.
8. Patients who are participating or have participated in any clinical trial within the 3 months previous to their inclusion in the study.
9. Patients who are drug abuse consumers.
10. Patients under treatment with antibiotics, sulphamides and antiparasitics, who cannot suspend the treatments 7 days prior to the performance of the hydrogen breath test.
11. Patients with any recognized and already existing disorder that might interfere with the any of the lactose intolerance diagnosis tests.
12. Patients who have taken aspirin of indomethacin in the 48h preceding the performance of the Gaxilose test.
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

VenterPharma

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Laura Crespo, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Hospital Universitario Ramón y Cajal

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Universitario Marqués de Valdecilla

Santander, Cantabria, Spain

Site Status

Hospital Universitario Doctor Josep Trueta

Girona, Girona, Spain

Site Status

Hospital Universitario de Getafe

Getafe, Madrid, Spain

Site Status

Hospital Universitario de La Princesa

Madrid, Madrid, Spain

Site Status

Hospital Universitario Ramón y Cajal

Madrid, Madrid, Spain

Site Status

Hospital Universitario Virgen de la Victoria

Málaga, Málaga, Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

References

Explore related publications, articles, or registry entries linked to this study.

Aragon JJ, Hermida C, Martinez-Costa OH, Sanchez V, Martin I, Sanchez JJ, Codoceo R, Cano JM, Cano A, Crespo L, Torres Y, Garcia FJ, Fernandez-Mayoralas A, Solera J, Martinez P. Noninvasive diagnosis of hypolactasia with 4-Galactosylxylose (Gaxilose): a multicentre, open-label, phase IIB-III nonrandomized trial. J Clin Gastroenterol. 2014 Jan;48(1):29-36. doi: 10.1097/MCG.0b013e318297fb10.

Reference Type BACKGROUND
PMID: 23722657 (View on PubMed)

Chinn S. Statistics in respiratory medicine. 2. Repeatability and method comparison. Thorax. 1991 Jun;46(6):454-6. doi: 10.1136/thx.46.6.454. No abstract available.

Reference Type BACKGROUND
PMID: 1858087 (View on PubMed)

Landis JR, Koch GG. An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics. 1977 Jun;33(2):363-74. No abstract available.

Reference Type BACKGROUND
PMID: 884196 (View on PubMed)

Sahi T. Genetics and epidemiology of adult-type hypolactasia. Scand J Gastroenterol Suppl. 1994;202:7-20. doi: 10.3109/00365529409091740.

Reference Type BACKGROUND
PMID: 8042019 (View on PubMed)

Villako K, Maaroos H. Clinical picture of hypolactasia and lactose intolerance. Scand J Gastroenterol Suppl. 1994;202:36-54. doi: 10.3109/00365529409091743.

Reference Type BACKGROUND
PMID: 8042017 (View on PubMed)

Suchy FJ, Brannon PM, Carpenter TO, Fernandez JR, Gilsanz V, Gould JB, Hall K, Hui SL, Lupton J, Mennella J, Miller NJ, Osganian SK, Sellmeyer DE, Wolf MA. NIH consensus development conference statement: Lactose intolerance and health. NIH Consens State Sci Statements. 2010 Feb 24;27(2):1-27.

Reference Type BACKGROUND
PMID: 20186234 (View on PubMed)

Newcomer AD, McGill DB, Thomas PJ, Hofmann AF. Prospective comparison of indirect methods for detecting lactase deficiency. N Engl J Med. 1975 Dec 11;293(24):1232-6. doi: 10.1056/NEJM197512112932405.

Reference Type BACKGROUND
PMID: 1186802 (View on PubMed)

Jellema P, Schellevis FG, van der Windt DA, Kneepkens CM, van der Horst HE. Lactose malabsorption and intolerance: a systematic review on the diagnostic value of gastrointestinal symptoms and self-reported milk intolerance. QJM. 2010 Aug;103(8):555-72. doi: 10.1093/qjmed/hcq082. Epub 2010 Jun 3.

Reference Type BACKGROUND
PMID: 20522486 (View on PubMed)

Shaukat A, Levitt MD, Taylor BC, MacDonald R, Shamliyan TA, Kane RL, Wilt TJ. Systematic review: effective management strategies for lactose intolerance. Ann Intern Med. 2010 Jun 15;152(12):797-803. doi: 10.7326/0003-4819-152-12-201006150-00241. Epub 2010 Apr 19.

Reference Type BACKGROUND
PMID: 20404262 (View on PubMed)

Newcomer AD, McGill DB. Distribution of disaccharidase activity in the small bowel of normal and lactase-deficient subjects. Gastroenterology. 1966 Oct;51(4):481-8. No abstract available.

Reference Type BACKGROUND
PMID: 5922947 (View on PubMed)

Hovde O, Farup PG. A comparison of diagnostic tests for lactose malabsorption--which one is the best? BMC Gastroenterol. 2009 Oct 31;9:82. doi: 10.1186/1471-230X-9-82.

Reference Type BACKGROUND
PMID: 19878587 (View on PubMed)

Arola H. Diagnosis of hypolactasia and lactose malabsorption. Scand J Gastroenterol Suppl. 1994;202:26-35. doi: 10.3109/00365529409091742.

Reference Type BACKGROUND
PMID: 8042016 (View on PubMed)

Aragon JJ, Canada FJ, Fernandez-Mayoralas A, Lopez R, Martin-Lomas M, Villanueva D. A direct enzymatic synthesis of beta-D-galactopyranosyl-D-xylopyranosides and their use to evaluate rat intestinal lactase activity in vivo. Carbohydr Res. 1996 Sep 2;290(2):209-16. doi: 10.1016/0008-6215(96)00113-9.

Reference Type BACKGROUND
PMID: 8823908 (View on PubMed)

Hermida C, Corrales G, Canada FJ, Aragon JJ, Fernandez-Mayoralas A. Optimizing the enzymatic synthesis of beta-D-galactopyranosyl-D-xyloses for their use in the evaluation of lactase activity in vivo. Bioorg Med Chem. 2007 Jul 15;15(14):4836-40. doi: 10.1016/j.bmc.2007.04.067. Epub 2007 May 6.

Reference Type BACKGROUND
PMID: 17512743 (View on PubMed)

Hermida C, Guerra P, Martinez-Costa OH, Sanchez V, Sanchez JJ, Solera J, Fernandez-Mayoralas A, Codoceo R, Frias J, Aragon JJ. Phase I and phase IB clinical trials for the noninvasive evaluation of intestinal lactase with 4-galactosylxylose (gaxilose). J Clin Gastroenterol. 2013 Jul;47(6):501-8. doi: 10.1097/MCG.0b013e318272f507.

Reference Type BACKGROUND
PMID: 23328304 (View on PubMed)

Lord SJ, Irwig L, Simes RJ. When is measuring sensitivity and specificity sufficient to evaluate a diagnostic test, and when do we need randomized trials? Ann Intern Med. 2006 Jun 6;144(11):850-5. doi: 10.7326/0003-4819-144-11-200606060-00011.

Reference Type BACKGROUND
PMID: 16754927 (View on PubMed)

Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. Med Decis Making. 1991 Apr-Jun;11(2):88-94. doi: 10.1177/0272989X9101100203.

Reference Type BACKGROUND
PMID: 1907710 (View on PubMed)

Lijmer JG, Leeflang M, Bossuyt PM. Proposals for a phased evaluation of medical tests. Med Decis Making. 2009 Sep-Oct;29(5):E13-21. doi: 10.1177/0272989X09336144. Epub 2009 Jul 15.

Reference Type BACKGROUND
PMID: 19605881 (View on PubMed)

Van den Bruel A, Cleemput I, Aertgeerts B, Ramaekers D, Buntinx F. The evaluation of diagnostic tests: evidence on technical and diagnostic accuracy, impact on patient outcome and cost-effectiveness is needed. J Clin Epidemiol. 2007 Nov;60(11):1116-22. doi: 10.1016/j.jclinepi.2007.03.015. Epub 2007 Aug 29.

Reference Type BACKGROUND
PMID: 17938052 (View on PubMed)

Blanchard TK, Mackenzie R, Bearcroft PW, Sinnatamby R, Gray A, Lomas DJ, Constant CR, Dixon AK. Magnetic resonance imaging of the shoulder: assessment of effectiveness. Clin Radiol. 1997 May;52(5):363-8. doi: 10.1016/s0009-9260(97)80131-6.

Reference Type BACKGROUND
PMID: 9171790 (View on PubMed)

Stanko LK, Jacobsohn E, Tam JW, De Wet CJ, Avidan M. Transthoracic echocardiography: impact on diagnosis and management in tertiary care intensive care units. Anaesth Intensive Care. 2005 Aug;33(4):492-6. doi: 10.1177/0310057X0503300411.

Reference Type BACKGROUND
PMID: 16119491 (View on PubMed)

Blaivas M, Kuhn W, Reynolds B, Brannam L. Change in differential diagnosis and patient management with the use of portable ultrasound in a remote setting. Wilderness Environ Med. 2005 Spring;16(1):38-41. doi: 10.1580/1080-6032(2005)16[38:ciddap]2.0.co;2.

Reference Type BACKGROUND
PMID: 15813146 (View on PubMed)

Hobby JL, Dixon AK, Bearcroft PW, Tom BD, Lomas DJ, Rushton N, Matthewson MH. MR imaging of the wrist: effect on clinical diagnosis and patient care. Radiology. 2001 Sep;220(3):589-93. doi: 10.1148/radiol.2203001429.

Reference Type BACKGROUND
PMID: 11526253 (View on PubMed)

Wilt TJ, Shaukat A, Shamliyan T, Taylor BC, MacDonald R, Tacklind J, Rutks I, Schwarzenberg SJ, Kane RL, Levitt M. Lactose intolerance and health. Evid Rep Technol Assess (Full Rep). 2010 Feb;(192):1-410.

Reference Type BACKGROUND
PMID: 20629478 (View on PubMed)

Srinivasan U, Jones E, Weir DG, Feighery C. Lactase enzyme, detected immunohistochemically, is lost in active celiac disease, but unaffected by oats challenge. Am J Gastroenterol. 1999 Oct;94(10):2936-41. doi: 10.1111/j.1572-0241.1999.01441.x.

Reference Type BACKGROUND
PMID: 10520848 (View on PubMed)

Phillips AD, Avigad S, Sacks J, Rice SJ, France NE, Walker-Smith JA. Microvillous surface area in secondary disaccharidase deficiency. Gut. 1980 Jan;21(1):44-8. doi: 10.1136/gut.21.1.44.

Reference Type BACKGROUND
PMID: 7364319 (View on PubMed)

Kaufman SS, Lyden ER, Brown CR, Iverson AK, Davis CK, Sudan DL, Fox IJ, Horslen SP, Shaw BW Jr, Langnas AN. Disaccharidase activities and fat assimilation in pediatric patients after intestinal transplantation. Transplantation. 2000 Feb 15;69(3):362-5. doi: 10.1097/00007890-200002150-00009.

Reference Type BACKGROUND
PMID: 10706043 (View on PubMed)

Kirschner BS, DeFavaro MV, Jensen W. Lactose malabsorption in children and adolescents with inflammatory bowel disease. Gastroenterology. 1981 Nov;81(5):829-32.

Reference Type BACKGROUND
PMID: 6895202 (View on PubMed)

Van Biervliet S, Eggermont E, Carchon H, Veereman G, Deboeck K. Small intestinal brush border enzymes in cystic fibrosis. Acta Gastroenterol Belg. 1999 Jul-Sep;62(3):267-71.

Reference Type BACKGROUND
PMID: 10547891 (View on PubMed)

Parnes HL, Fung E, Schiffer CA. Chemotherapy-induced lactose intolerance in adults. Cancer. 1994 Sep 1;74(5):1629-33. doi: 10.1002/1097-0142(19940901)74:53.0.co;2-l.

Reference Type BACKGROUND
PMID: 8062196 (View on PubMed)

Bond JH, Levitt MD. Quantitative measurement of lactose absorption. Gastroenterology. 1976 Jun;70(6):1058-62.

Reference Type BACKGROUND
PMID: 1269865 (View on PubMed)

Maxwell C. Sensitivity and accuracy of the visual analogue scale: a psycho-physical classroom experiment. Br J Clin Pharmacol. 1978 Jul;6(1):15-24. doi: 10.1111/j.1365-2125.1978.tb01676.x.

Reference Type BACKGROUND
PMID: 666944 (View on PubMed)

Wewers ME, Lowe NK. A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health. 1990 Aug;13(4):227-36. doi: 10.1002/nur.4770130405.

Reference Type BACKGROUND
PMID: 2197679 (View on PubMed)

Hobby JL, Tom BD, Todd C, Bearcroft PW, Dixon AK. Communication of doubt and certainty in radiological reports. Br J Radiol. 2000 Sep;73(873):999-1001. doi: 10.1259/bjr.73.873.11064655.

Reference Type BACKGROUND
PMID: 11064655 (View on PubMed)

Dixon AK. The impact of medical imaging on the physician's diagnostic and therapeutic thinking. Eur Radiol. 1998;8(3):488-90. doi: 10.1007/s003300050423. No abstract available.

Reference Type BACKGROUND
PMID: 9510594 (View on PubMed)

Mackenzie R, Dixon AK, Keene GS, Hollingworth W, Lomas DJ, Villar RN. Magnetic resonance imaging of the knee: assessment of effectiveness. Clin Radiol. 1996 Apr;51(4):245-50. doi: 10.1016/s0009-9260(96)80340-0.

Reference Type BACKGROUND
PMID: 8617035 (View on PubMed)

Pitkanen E. The conversion of D-xylose into D-threitol in patients without liver disease and in patients with portal liver cirrhosis. Clin Chim Acta. 1977 Oct 1;80(1):49-54. doi: 10.1016/0009-8981(77)90262-5.

Reference Type BACKGROUND
PMID: 908147 (View on PubMed)

CRANE RK. Intestinal absorption of sugars. Physiol Rev. 1960 Oct;40:789-825. doi: 10.1152/physrev.1960.40.4.789. No abstract available.

Reference Type BACKGROUND
PMID: 13696269 (View on PubMed)

Monsalve-Hernando C, Crespo L, Ferreiro B, Martin V, Aldeguer X, Opio V, Fernandez-Gil PL, Gaspar MJ, Romero E, Lara C, Santander C, Torrealba L, Savescu T, Hermida C. Phase IV noninferiority controlled randomized trial to evaluate the impact on diagnostic thinking and patient management and the test-retest reproducibility of the Gaxilose test for hypolactasia diagnosis. Medicine (Baltimore). 2018 Nov;97(46):e13136. doi: 10.1097/MD.0000000000013136.

Reference Type DERIVED
PMID: 30431582 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2015-001181-26

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

VPH-GXL-2013-01

Identifier Type: -

Identifier Source: org_study_id